Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

1. D Boral Capital initiates coverage on Tevogen Bio with a Buy rating. 2. Tevogen's pipeline includes therapies for various cancers and autoimmune diseases. 3. Analyst forecasts price target of $10 for TVGN, emphasizing growth potential. 4. Recent $10 million grant funding supports Tevogen's AI initiatives and growth. 5. TVGN stock rose 9.32% following the positive analyst coverage.